Trial Profile
AXITINIB IN ADVANCED / METASTATIC RENAL CELL CARCINOMA - A NON-INTERVENTIONAL STUDY OF REAL WORLD TREATMENT OUTCOMES IN PATIENTS RECEIVING 2ND LINE AXITINIB AFTER 1ST LINE SUNITINIB (ADONIS)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs Axitinib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms ADONIS
- Sponsors Pfizer
- 03 Nov 2021 Status changed from recruiting to completed.
- 12 Oct 2019 Planned End Date changed from 20 Jul 2019 to 1 May 2021.
- 12 Oct 2019 Planned primary completion date changed from 20 Jul 2019 to 1 May 2021.